
Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly
AbbVie execs have finally gotten around to doing what a host of analysts managed to accomplish long ago: writing down the value of their once much-vaunted cancer drug Rova-T.
Way down.
On Friday the company filed a notice with the SEC explaining that AbbVie $ABBV has decided to knock $4 billion off the book value of the drug weeks after researchers were forced to stop recruiting patients in the now infamous TAHOE study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.